As we all know, the five FDA-approved medications for dementia with Alzheimer’s symptoms can only temporarily alleviate symptoms; they do not delay, stop, or reverse the disease progress.
I want you to know about a natural food supplement extracted from the sea scallop, which has been clinically proven to improve cognitive function, behavior, emotion, and life quality of Alzheimer’s and dementia patients!
I am pleased to share this promising news that comes to us from a research team at Kyushu University in Japan led by Dr. Takehiko Fujino, Professor Emeritus of Kyushu University.
Our appreciation goes to Dr. Crystal Goh, Ph.D., Health Biotechnology, and Scientific Officer for Lifestream Group Pte Ltd., Singapore for contributing the article that we are about to enjoy. Dr. Goh was a part of this research project.
I have reproduced the article in full as it contains much useful information and even some patient video interviews. Here goes:
Scallop-derived PLASMALOGEN – the most promising solution for Alzheimer’s and dementia
With a deep passion to find a solution for Alzheimer’s and dementia, Emeritus Professor Takehiko Fujino (M.D., Ph.D.) from Kyushu University in Japan recently discovered a most promising solution for Alzheimer’s and dementia – Scallop-derived PLASMALOGEN! This plasmalogen was clinically proven to improve cognitive function, behaviour, emotion and life quality of Alzheimer’s and dementia patients. Finally, a ray of hope is shining for these patients and their loved ones.
Plasmalogen – a vital component in the brain
Plasmalogens are a type of phospholipid present in almost all tissues of human beings and are most abundant in the brain. Plasmalogen level in the brain begins to increase from fetal stage and reach its peak by the 30s and start to decline thereafter.
Since 1995, researchers from Europe and US have found that Alzheimer’s patients have lower plasmalogen levels in the brain and blood serum compared to normal healthy persons. However, the research has made very little progress. In 2006, Professor Fujino and his team successfully developed a patented high-volume plasmalogen extraction method to extract 92% purity plasmalogens for animal testing and clinical trials on patients. Animal testing has shown that plasmalogens are critical for brain health and mental function. Through the animal testing, this team has discovered that plasmalogens:
- Suppress accumulation of amyloid β proteins. These proteins will form amyloid plaque in the brain, which is one of the hallmarks of Alzheimer’s.
LPS activated accumulation of amyloid β proteins while simultaneous application of plasmalogens suppressed these proteins in the hippocampus of mice. Neurons were stained with NeuN which is shown in red (a – c). Control group treated with saline showed a slight fluorescent of amyloid β immunoreactivity (green) (d). LPS treatment increased the accumulation of amyloid β proteins (e) and these proteins were completely eradicated by plasmalogen treatment (f). Amyloid β and NeuN fluorescences were merged to show an intracellular location of amyloid β in the neurons (g and h) (Katafuchi et al., 2012).
Protect against neuronal (nerve) cell death in brain. Neuronal loss causes brain atrophy which is a prominent pathological characteristic of Alzheimer’s.
Plasmalogens inhibited hippocampal neuronal cell death in mice. Number of survived neuronal cells decreased to about 50% when cultured in nutrient-deprived medium. (A) These nutrient-deprived neuronal cells were then treated with plasmlogens for 72 hours. Survival rate significantly increased in these neuronal cells treated with plasmalogens compared with nutrient-deprived control neuronal cells. These neuronal cells were stained with Dil (red colour). Scale bar, 50 μm. (B) The bars show the number of primary hippocampal neuronal cells in the specific area of 12 randomly selected locations from each cell culture dish. The data represents average ± standard deviation from four independent experiments with significant differences between control and plasmalogen-treated groups (Bonferroni’s test, P < 0.001) (Hossain MS et al., 2013).
Improve learning and memory function. Video of this animal testing can be viewed at: https://www.facebook.com/plasmalogens/videos/1748410992114426/
- Promote neurogenesis (growth of new nerve cells). Professor Fujino concludes that “It is unnecessary to improve cells destroyed by amyloid β protein if new cells are born. We believe that this very action, neurogenesis is the new treatment for dementia”.
World’s first discovery of plasmalogen-induced neurogenesis. Neurogenesis occurred in hippocampal dentate gyrus of a normal mouse resulted in denser cells (darker colour) (A). Neurogenesis did not occur in mouse with inflammation (C). After administration of plasmalogens, the condition in mouse with inflammation was restored to normal (D) as in normal mouse (B).
Clinical trial of Scallop-derived PLASMALOGEN
With impressive results from the animal testing, Professor Fujino has decided to conduct a clinical trial of plasmalogen on Alzheimer’s and dementia patients. As plasmalogen extracted from scallop is enriched with DHA and EPA and its chemical structure is closest to those found in the human body, this research team decided to use Scallop-derived PLASMALOGEN which they extracted from scallop. Scallop-derived PLASMALOGEN is completely natural without any chemical modification. In 2015, a large-scale clinical trial which involved 225 patients with moderate and severe Alzheimer’s, Lewy body, cerebrovascular and semantic dementia (60 – 85 years old) was conducted to test the effectiveness of Scallop-derived PLASMALOGEN on these patients after continuous intake for 3 months. This trial was completed in April 2016. Currently, the interim report based on 44 patients who had completed the earlier trial is available. The full data from 225 patients is expected to be published late 2016 or 2017.
Based on the clinical data from 44 patients, ingestion of Scallop-derived PLASMALOGEN replenished blood plasmalogen levels in the patients. This plasmalogen restoration therapy was proven to
- Improve cognitive function. 71% and 46% of patients with moderate and severe dementia respectively showed improvement in cognitive function as assessed through MMSE test. MMSE is a test that is used internationally to help in the diagnosis of dementia. It assesses the memory, concentration, orientation, language and visual-spatial skills to determine the progression and severity of the disease. The higher the MMSE score, the better the cognitive function.
- Improve behavioural symptoms. More than 80% of dementia patients showed reduced incidences of hallucination. In addition, more than 50% of patients demonstrated improvement in delusional states, depression and hygiene awareness. Furthermore, improvement of sleep disorder and urinary incontinence were also observed among the patients.
- Improve facial expression and emotion. More than 90% of patients showed an improvement in expressing emotions with bright facial expression. Moreover, they are also more aware and concerned about their surroundings after ingesting Scallop-derived PLASMALOGEN.
Real case studies of Scallop-derived PLASMALOGEN on dementia patients
The clinically proven results are recognized by dementia specialists in Japan who recommended it as a natural therapy for their Alzheimer’s and dementia patients. I am enthusiastic to share some of the case studies with you here.
Case 1: Improvement from moderate to mild stage of dementia
Kiyoshi was diagnosed with semantic dementia for 3 years, which is characterised by language difficulty such as inability to understand words. His MMSE score before taking Scallop-derived PLASMALOGEN was just 18 points, indicating moderate stage of dementia. However, his MMSE score increased to 23 points (mild stage) just 1 month after taking Scallop-derived PLASMALOGEN. Watch video at:
Case 2: Most amazing improvement seen by research team
This 81-year-old Japanese woman was diagnosed with Lewy body dementia which is characterised by symptoms such as hallucinations. Before the intake of Scallop-derived PLASMALOGEN, the patient was not very responsive when the doctor greeted her and sough permission to examine her. Remarkably, she showed dramatic changes just 2 weeks after the administration of Scallop-derived PLASMALOGEN. Watch video at:
I am very honored for the privilege to be a part of this project to help Alzheimer’s and dementia sufferers improve and regain their quality of life and dignity. We hope to empower caregivers whose lives are also impacted by the immense physical, mental and financial stress of caring for their loved ones. I sincerely hope this article will be able to give caregivers the hope, strength and courage to go through this unimaginably difficult time. With this available option of natural dietary supplementation, Alzheimer’s and dementia are no longer fatal. This latest development will transform the lives of millions of people. If you are able, please like our Facebook page or share this article, videos or website to save more lives.
You can visit http://plasmalogen.me/ if you are interested to find out more about clinical trials of Scallop-derived PLASMALOGEN. Please feel free to email me at firstname.lastname@example.org if you need any further information. I also wish to share with you that The 1st International Plasmalogen Symposium will be held on November 7 and 8, 2016, in School of Medicine, Kyushu University in Japan. Please visit http://plssympo.com/index.html for more details.
Thank you, Dr. Goh, for contributing this most relevant information!